Dermatology

RheumMadness

RheumMadness

Questions discussed in this category

What is your experience with using oral deucravacitinib off label for conditions such as recalcitrant facial discoid lupus or recalcitrant lichen planus?

Do you have thoughts in general about the potential of TYK2 inhibition for these difficult to treat diseases?This question is part of a collaboration ...

1 Answer available

How do you optimize retinopathy screening schedules for patients on hydroxychloroquine while also prioritizing cost-effectiveness?

This question is part of a collaboration with RheumMadness and is specifically in reference to: Cost Effectiveness of HCQ Screening.

3 Answers available

How will you utilize newly FDA approved anifrolumab for SLE in your practice?

This question is part of a collaboration with RheumMadness and is specifically in reference to: Long-term outcomes of anifrolumab in SLE.

2 Answers available

What circumstances would drive you to consider using an oral IL-23 inhibitor over parenteral options for the management of psoriasis and/or psoriatic arthritis?

This question is part of a collaboration with RheumMadness and is specifically in reference to: Bissonnette et al., PMID 38324484

2 Answers available

What is your approach to monitoring for hepatic fibrosis in chronic methotrexate use?

Do you frequently order liver biopsies for these patients?This question is part of a collaboration with RheumMadness and is specifically in reference ...

2 Answers available

How will you sequence therapies in dermatomyositis given the results of the ProDERM trial?

Will you still favor starting with steroids and traditional immunosuppressive agents, move IVIG earlier in your treatment strategy, or start with IVIG...

3 Answers available

Is there a role for monitoring serum ANCAs to assess ANCA associated vasculitis disease activity?

This question is part of a collaboration with RheumMadness and is in reference to Pathogenic ANCA (RAVE Trial).

2 Answers available

How do you counsel patients who ask if there are any dietary modifications they can make to help control their autoimmune disease?

This question is part of a collaboration with RheumMadness and is specifically in reference to: ADIRA Diet

1 Answer available

Papers discussed in this category

Ann. Rheum. Dis., 2018 Apr 25

Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).

Autoimmunity reviews, 2009-02

The risk of ultraviolet radiation exposure from indoor lamps in lupus erythematosus.

Journal of the American Academy of Dermatology, 2011-05

Quality of life in cutaneous lupus erythematosus.

Arthritis and rheumatism, 2013-07

Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio.

Arthritis Rheumatol, 2021 Mar 24

Long-Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open-Label Extension Study.

Rev Med Interne, 2016 Oct 13

[Blood concentration of hydroxychloroquine in systemic lupus erythematosus care: Usefulness and limits].

Arthritis Care Res (Hoboken), 2021 Mar 30

Clinical Significance of Monitoring Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.

JAMA Dermatol,

Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study.

Mod Rheumatol, 2020 Sep 17

Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials.

Ann Rheum Dis, 2014 Feb 13

The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort.

Ann Rheum Dis, 2019 Jan 04

Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis.

Ann Rheum Dis, 2014 Apr 16

Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.

Arthritis & rheumatology (Hoboken, N.J.), 2023 Jun 01

Comparative Risks of Infection With Belimumab Versus Oral Immunosuppressants in Patients With Nonrenal Systemic Lupus Erythematosus.

Annals of the rheumatic diseases, 2023 Oct 12

EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.

Lupus science & medicine, 2024 May 22

Disease-modifying therapies in systemic lupus erythematosus for extrarenal manifestations.

The Lancet. Rheumatology, 2019 Nov 25

Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study.

N Engl J Med, 2019 Dec 18

Trial of Anifrolumab in Active Systemic Lupus Erythematosus.

Arthritis care & research, 2014-08

Identification of risk factors for elevated transaminases in methotrexate users through an electronic health record.

Intern Med J, 2022 Mar 16

Assessment of liver fibrosis markers in people with rheumatoid arthritis on methotrexate.

The New England journal of medicine, 1993-12-30

A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis.

N Engl J Med, 2022 Oct 06

Trial of Intravenous Immune Globulin in Dermatomyositis.

The New England journal of medicine, 2024 Feb 08

An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis.

Arthritis & rheumatology (Hoboken, N.J.), 2021 Apr 26

American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 Joint Statement on Hydroxychloroquine Use With Respect to Retinal Toxicity.

Ophthalmology, 2016-06

Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).

Related Topics in Dermatology